• Malte Ziemann, Matthias Heringlake, Philipp Lenor, David Juhl, Thorsten Hanke, Michael Petersen, Julika Schön, Hermann Heinze, Heinrich V Groesdonk, Hauke Paarmann, and Holger Hennig.
• Institute of Transfusion Medicine, University Hospital of Schleswig-Holstein. Electronic address: Malte.Ziemann@uksh.de.
• J. Cardiothorac. Vasc. Anesth. 2017 Dec 1; 31 (6): 2042-2048.

ObjectiveTo clarify whether reactivated cytomegalovirus (CMV) infections in critically ill patients lead to worse outcome or just identify more severely ill patients. If CMV has a pathogenic role, latently infected (CMV-seropositive) patients should have worse outcome than seronegative patients because only seropositive patients can experience a CMV reactivation.DesignPost-hoc analysis of a prospective observational study.SettingSingle university hospital.ParticipantsThe study comprised 983 consecutive patients scheduled for on-pump surgery.InterventionsNone.Measurements And Main ResultsCMV antibodies were analyzed in preoperative plasma samples. Postoperative adverse events (reintubation, low cardiac output or reinfarction, dialysis, stroke) and 30-day and 1-year mortality were evaluated prospectively. The plasma of reintubated patients and matched control patients was tested for CMV deoxyribonucleic acid, and 618 patients were found to be seropositive for CMV (63%). Among these, the risk for reintubation was increased (10% v 4%, p = 0.001). This increase remained significant after correction for confounding factors (odds ratio 2.70, p = 0.003) and was detectable from the third postoperative day throughout the whole postoperative period. Other outcome parameters were not different. Reintubated seropositive patients were more frequently CMV deoxyribonucleic acid-positive than were matched control patients (40% v 8%, p<0.001).ConclusionsCMV-seropositive patients had an increased risk of reintubation after cardiac surgery, which was associated with reactivations of their CMV infections. Additional studies should determine whether this complication may be prevented by monitoring of latently infected patients and administering antiviral treatment for reactivated CMV infections.Copyright © 2016 Elsevier Inc. All rights reserved.

28 keywords...

hide…